샘플 요청 목록

 카트 문의
시장보고서
상품코드
1742800

세계의 꽃가루 알레르기 시장

Pollen Allergy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 498 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 꽃가루 알레르기 시장은 2030년까지 67억 달러에 이를 전망

2024년에 54억 달러로 추정되는 꽃가루 알레르기 세계 시장은 2024-2030년간 CAGR 3.8%로 성장하여 2030년에는 67억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 기기는 CAGR 4.2%를 나타내고, 분석 기간 종료시에는 44억 달러에 이를 것으로 예측됩니다. 소모품 부문의 성장률은 분석 기간중 CAGR 3.0%로 추정됩니다.

미국 시장은 15억 달러, 중국은 CAGR 7.0%로 성장 예측

미국의 꽃가루 알레르기 시장은 2024년에 15억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 14억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 7.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.5%와 2.9%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%를 보일 전망입니다.

세계의 꽃가루 알레르기 시장 - 주요 동향과 촉진요인 정리

꽃가루 알레르기가 전 세계 공중보건 문제로 떠오른 이유는 무엇일까?

의학적으로 계절성 알레르기성 비염 또는 꽃가루 알레르기로 불리는 꽃가루 알레르기는 전 세계적으로 수억 명의 사람들에게 영향을 미치는 공중 보건 문제로 확산되고 있습니다. 코막힘, 재채기, 눈물, 호흡기 불편감 등의 증상을 특징으로 하는 이 증상은 풀, 잡초, 나무 꽃가루에 대한 면역 체계의 과민 반응으로 인해 발생합니다. 꽃가루 알레르기의 유병률 증가는 도시화, 기후 변화, 대기오염 증가, 꽃가루가 날리는 시기의 연장과 밀접한 관계가 있습니다.

도시 지역에서는 '도시 열섬' 효과와 조경을 통한 알레르기 유발 식물 종 증가로 인해 알레르기 발병률이 높아지고 있습니다. 또한, 산업 배기가스와 디젤 미립자가 꽃가루와 상호 작용하여 알레르기 유발 물질을 증가시켜 민감한 사람들의 증상을 악화시키고 있습니다. 이러한 추세는 선진국에 국한된 것이 아니라 아시아태평양, 라틴아메리카, 아프리카의 일부 지역에서도 진단율이 증가하고 있으며, 특히 삶의 질 저하와 생산성 저하로 고통받는 어린이, 청소년 및 일하는 성인들 사이에서 꽃가루 알레르기가 빠르게 전 세계적으로 유행하고 있음을 강조하고 있습니다.

효과적인 증상 관리를 위해 진단 및 치료 전략은 어떻게 진화하고 있는가?

꽃가루 알레르기의 진단을 위해 기존에는 피부 도말 검사, 혈액 내 IgE 측정, 병력 분석 등이 사용되어 왔습니다. 그러나 최근 분자진단학의 발전으로 알레르겐 성분 분해 진단(CRD)을 통해 과민반응을 일으키는 꽃가루의 특정 단백질을 정확하게 확인할 수 있게 되었으며, 특히 여러 환경 알레르겐에 반응하는 다감작자에서 CRD는 면역치료 접근법을 조정하고 교차반응을 최소화하는 데 도움이 됩니다. 교차 반응성을 최소화하는 데 도움을 주고 있습니다.

약리학적 관리에는 항히스타민제, 비강 내 코르티코스테로이드, 류코트리엔 수용체 길항제, 충혈제거제 등이 있으며, 여러 증상을 조절하기 위한 병용요법에 대한 관심이 증가하고 있습니다. 알레르기 항원 면역요법(AIT)은 피하(SCIT) 또는 설하(SLIT)로 시행되며, 현재로서는 유일한 장기적인 질환 조절 치료법으로, 알레르기 항원 노출을 조절하여 면역계를 감작시켜 알레르기 비염에서 천식으로의 진행을 예방할 수 있는 가능성이 있기 때문에 점점 더 인기를 얻고 있습니다. 인기를 얻고 있습니다. 일반의약품(OTC) 알레르기 치료제, 공기 여과 장치, 꽃가루 예측을 위한 모바일 건강 앱은 전 세계 환자들의 증상 회피와 자가 관리를 돕고 있습니다.

진단약, 의료 제공 형태, 커뮤니티 케어 모델의 혁신은 어디에서 일어나고 있는가?

꽃가루 알레르기 시장의 혁신은 의약품에 국한되지 않고 진단약, 전달 시스템, 디지털 치료제에 이르기까지 다양합니다. 면역 요법이나 정량적 비강 점비제를 위한 바늘 없는 전달 장치는 환자의 순응도를 높이고 불편함을 줄여주고 있습니다. 생명공학 기업들은 저알레르기 재조합 꽃가루 알레르겐과 보조제 강화 면역치료제를 개발하여 효능을 향상시키고 부작용을 감소시키고 있습니다. 이러한 기술은 특히 고소득층 시장에서 개인 맞춤형 알레르기 치료로 전환하고 있습니다.

디지털을 활용한 케어 모델도 등장하고 있습니다. 웨어러블 공기질 센서, 꽃가루 비산 모델과 통합된 스마트폰 앱, 원격 상담 서비스를 통해 환자들은 유발 요인을 예측하고 적시에 의료 지원을 받을 수 있습니다. 지역별로는 유럽이 알레르기 연구 및 치료의 최전선에 있으며, 북미는 OTC 및 면역치료 제품의 상업적 보급이 활발히 진행되고 있습니다. 아시아태평양은 알레르기 질환에 대한 인식 증가, 도시 대기 환경 문제, 헬스케어 투자 증가 등을 배경으로 높은 잠재력을 가진 시장으로 부상하고 있습니다. 각국 정부는 알레르기에 취약한 사람들을 보다 적극적으로 식별하고 관리하기 위해 학교와 직장에서의 선별검사 프로그램을 시작하고 있습니다.

꽃가루 알레르기 세계 시장 성장 가속화의 원동력은?

세계 꽃가루 알레르기 시장의 성장은 알레르기성 비염의 전 세계 유병률 증가, 대기 환경 악화, 기후 변화에 따른 꽃가루 날림 기간의 장기화 등 여러 요인에 의해 주도되고 있습니다. 환경에 대한 인식 증가, 알레르기 진단 방법의 개선, OTC 항히스타민제 및 면역 치료 솔루션의 광범위한 가용성은 시장 확대에 더욱 기여하고 있습니다. 의료 시스템도 알레르기성 비염이 학교 결석, 결근, 부비동염, 천식 등의 동반 질환으로 이어지는 알레르기성 비염의 사회경제적 영향을 인식하고 있습니다.

알레르기 검사, 예측 모델링, 디지털 헬스케어 분야의 기술 발전으로 조기 진단과 지속적인 치료가 강화되고 있습니다. 비진정성 항히스타민제, 비강용 코르티코스테로이드 복합제, 생물학적 제제 등의 치료 혁신으로 증상 조절이 개선되고 장기 치료 요법에서 환자의 이탈이 감소하고 있습니다. 예방적 건강관리, 환경 대책, 개인별 맞춤 면역요법이 강조되고, 특히 기후 변화로 인해 알레르겐의 분포 패턴이 계속 변화하고, 전 세계 알레르기 질환의 부담이 증가함에 따라 꽃가루 알레르기 시장은 강력한 성장이 예상됩니다.

부문

제품 유형(기기, 소모품, 서비스), 치료제 약제 클래스(항히스타민제, 울혈제거제, 부신피질 스테로이드제, 비만세포 안정화제, 류코트리엔 억제제, 비항콜린제, 면역조절제, 자동 주사 에피네프린, 면역치료), 알레르겐 유형(식품, 흡입, 약제, 기타 알레르겐 유형), 최종사용자(진단실험실, 병원, 기타 최종사용자)

조사 대상 기업 예(총 48개사)

  • AbbVie Inc.
  • Aimmune Therapeutics
  • Alcon Inc.
  • ALK-Abello A/S
  • Allergopharma
  • Allergy Therapeutics
  • ASIT Biotech SA
  • Bayer AG
  • Biomay AG
  • bioMerieux SA
  • Circassia Pharmaceuticals
  • DBV Technologies
  • Genentech Inc.
  • GlaxoSmithKline plc
  • HAL Allergy Group
  • HOB Biotech Group Corp Ltd
  • Johnson & Johnson
  • LETIPharma
  • Merck KGaA
  • Stallergenes Greer

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.18

Global Pollen Allergy Market to Reach US$6.7 Billion by 2030

The global market for Pollen Allergy estimated at US$5.4 Billion in the year 2024, is expected to reach US$6.7 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Consumables segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 7.0% CAGR

The Pollen Allergy market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Pollen Allergy Market - Key Trends & Drivers Summarized

Why Is Pollen Allergy Emerging as a Global Public Health Concern?

Pollen allergy, medically referred to as seasonal allergic rhinitis or hay fever, is becoming a widespread public health issue affecting hundreds of millions globally. Characterized by symptoms such as nasal congestion, sneezing, watery eyes, and respiratory discomfort, the condition results from hypersensitivity of the immune system to pollen from grasses, weeds, and trees. The growing prevalence of pollen-induced allergies is closely linked to urbanization, climate change, increased air pollution, and extended pollen seasons-factors that together intensify allergen exposure and severity.

Urban areas are reporting higher allergy rates due to the “urban heat island” effect and the proliferation of allergenic plant species in landscaping. Moreover, industrial emissions and diesel particulates interact with pollen grains, increasing their allergenicity and aggravating symptoms in sensitive populations. This trend is not limited to developed countries-rising diagnosis rates in Asia-Pacific, Latin America, and parts of Africa highlight that pollen allergy is fast becoming a global epidemic, particularly among children, adolescents, and working-age adults who suffer significant quality-of-life disruptions and productivity losses.

How Are Diagnosis and Therapeutic Strategies Evolving for Effective Symptom Management?

The diagnosis of pollen allergy traditionally involves skin prick tests, blood IgE assays, and clinical history analysis. However, recent developments in molecular diagnostics now enable allergen component-resolved diagnostics (CRD), which offer precise identification of the specific proteins within pollen that trigger hypersensitivity reactions. CRD is helping to tailor immunotherapy approaches and minimize cross-reactivity, especially in poly-sensitized individuals reacting to multiple environmental allergens.

Pharmacological management includes antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and decongestants, with growing interest in combination therapies for multi-symptom control. Allergen immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT), remains the only long-term disease-modifying treatment. AIT desensitizes the immune system through controlled allergen exposure and is gaining popularity due to its potential to prevent the progression of allergic rhinitis to asthma. Over-the-counter (OTC) allergy remedies, air filtration devices, and mobile health apps for pollen forecasting are further supporting symptom avoidance and self-management among patients worldwide.

Where Is Innovation Taking Shape Across Diagnostics, Delivery Formats, and Regional Care Models?

Innovation in the pollen allergy market is not confined to pharmaceuticals but spans across diagnostics, delivery systems, and digital therapeutics. Needle-free delivery devices for immunotherapy and metered-dose nasal sprays are enhancing patient adherence and reducing discomfort. Biotech firms are developing hypoallergenic recombinant pollen allergens and adjuvant-enhanced immunotherapy formulations for improved efficacy and reduced adverse reactions. These technologies are creating a shift toward personalized allergy care, especially in high-income markets.

Digitally enabled care models are also gaining ground. Wearable air quality sensors, smartphone apps integrated with pollen dispersion models, and teleconsultation services are empowering patients to anticipate triggers and access timely medical support. Regionally, Europe remains at the forefront in allergy research and treatment accessibility, while North America shows strong commercial uptake of OTC and immunotherapy products. Asia-Pacific is emerging as a high-potential market, driven by rising allergic disease awareness, urban air quality challenges, and increasing healthcare investments. Governments are initiating school and workplace screening programs to identify and manage allergy-prone populations more proactively.

What’s Driving the Accelerated Growth of the Global Pollen Allergy Market?

The growth in the global pollen allergy market is driven by several factors, including the rising global incidence of allergic rhinitis, worsening air quality, and longer pollen seasons linked to climate change. Increasing environmental awareness, improved allergy diagnostics, and broader availability of OTC antihistamines and immunotherapy solutions are further contributing to market expansion. Healthcare systems are also recognizing the socioeconomic impact of allergic rhinitis, which leads to missed school days, absenteeism, and comorbidities like sinusitis and asthma.

Technological advancements in allergy testing, predictive modeling, and digital health management are enhancing early diagnosis and sustained care. Pharmaceutical innovations in non-sedating antihistamines, nasal corticosteroid combinations, and biologics are improving symptom control and reducing patient dropout from long-term treatment regimens. With growing emphasis on preventive healthcare, environmental control measures, and personalized immunotherapy, the pollen allergy market is expected to witness robust growth, especially as climate change continues to alter allergen distribution patterns and intensify the global allergic disease burden.

SCOPE OF STUDY:

The report analyzes the Pollen Allergy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Consumables, Services); Therapeutics Drug Class (Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, Immunotherapy); Allergen Type (Food, Inhaled, Drug, Other Allergen Types); End-Use (Diagnostic Laboratories, Hospitals, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Aimmune Therapeutics
  • Alcon Inc.
  • ALK-Abello A/S
  • Allergopharma
  • Allergy Therapeutics
  • ASIT Biotech SA
  • Bayer AG
  • Biomay AG
  • bioMerieux SA
  • Circassia Pharmaceuticals
  • DBV Technologies
  • Genentech Inc.
  • GlaxoSmithKline plc
  • HAL Allergy Group
  • HOB Biotech Group Corp Ltd
  • Johnson & Johnson
  • LETIPharma
  • Merck KGaA
  • Stallergenes Greer

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pollen Allergy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Seasonal Allergic Rhinitis Spurs Growth in the Pollen Allergy Management Market
    • Expansion of Urbanization and Air Pollution Throws the Spotlight on Heightened Allergen Sensitization
    • Development of Non-Sedating Antihistamines and Long-Acting Therapies Enhances Daily Symptom Control
    • Growth in Immunotherapy and SLIT (Sublingual Immunotherapy) Adoption Expands Treatment Landscape
    • Innovation in Air Filtration, Pollen Barriers, and Nasal Sprays Drives Preventive Allergy Management
    • Increasing Demand for OTC Remedies and Natural Allergy Relief Products Fuels Consumer Healthcare Sales
    • Collaboration With ENT Specialists and Allergy Clinics Strengthens Integrated Treatment Approaches
    • Surge in Home and Portable Air Quality Devices Propels Pollen Monitoring Integration
    • Focus on Rapid Allergen Diagnostic Testing and Home Kits Enhances Consumer Empowerment
    • Growth in Biologics and Monoclonal Antibody Therapy Expands Options for Severe Allergy Management
    • Advances in Allergen Mapping and Pollen Forecasting Drive Personalized Treatment Solutions
    • Expansion of Mobile Health and Allergy Management Apps Spurs Digital Health Adoption in Allergy Control
    • Participation in Regulatory Guidelines for Allergy Medication Labeling Strengthens Safety Profiles
    • Increasing Awareness of Cross-Reactivity and Food-Pollen Syndrome Drives Demand for Educational Resources
    • Entry Into Pediatric Allergy Management Market Enhances Age-Specific Treatment Accessibility
    • Rising Popularity of Nasal Filters, HEPA Masks, and Wearables Strengthens Non-Pharmacological Product Category
    • Investment in Botanical and Non-Corticosteroid Therapeutics Enhances Natural Remedy Pipeline
    • Expansion of Allergy Care in Emerging Markets Through E-Pharmacy and Telehealth Platforms Supports Access
    • Differentiation Through Symptom Tracker Integration and Adherence Tools Improves Chronic Case Outcomes
    • Global Climate Change Patterns Alter Pollen Seasons, Increasing Duration and Intensity of Allergic Episodes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pollen Allergy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pollen Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pollen Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Pollen Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Auto injectable Epinephrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Auto injectable Epinephrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Auto injectable Epinephrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Decongestants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Mast Cell Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Mast Cell Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Mast Cell Stabilizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Leukotriene Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Leukotriene Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Leukotriene Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Nasal Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Nasal Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Nasal Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Food by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Food by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Food by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Inhaled by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Inhaled by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Inhaled by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Allergen Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Allergen Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Other Allergen Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 62: USA Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: USA 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Canada 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Japan 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 98: China Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Pollen Allergy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Pollen Allergy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Pollen Allergy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 125: France Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 161: UK Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: UK 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Spain 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Russia 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Pollen Allergy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Pollen Allergy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Australia 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Australia 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 236: India Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: India 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: India 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: South Korea 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: South Korea 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Pollen Allergy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Pollen Allergy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Latin America 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Latin America 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Argentina 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Argentina 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Brazil 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Brazil 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Mexico 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Mexico 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Rest of Latin America 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Pollen Allergy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Pollen Allergy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Middle East 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Middle East 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Iran 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Iran 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Israel 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Israel 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Saudi Arabia 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: UAE 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: UAE 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Rest of Middle East 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Pollen Allergy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Pollen Allergy by Product Type - Instruments, Consumables and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Pollen Allergy by Product Type - Instruments, Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Pollen Allergy by Product Type - Percentage Breakdown of Value Sales for Instruments, Consumables and Services for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Pollen Allergy by Therapeutics Drug Class - Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Pollen Allergy by Therapeutics Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Auto injectable Epinephrine, Immunotherapy, Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors and Nasal Anticholinergics for the Years 2015, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Pollen Allergy by Allergen Type - Food, Inhaled, Drug and Other Allergen Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Africa 15-Year Perspective for Pollen Allergy by Allergen Type - Percentage Breakdown of Value Sales for Food, Inhaled, Drug and Other Allergen Types for the Years 2015, 2025 & 2030
    • TABLE 419: Africa Recent Past, Current & Future Analysis for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Africa Historic Review for Pollen Allergy by End-Use - Diagnostic Laboratories, Hospitals and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Africa 15-Year Perspective for Pollen Allergy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories, Hospitals and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제